<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="DKK" hierarchy="2" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-3-1-270615-32457</iati-identifier>
  <reporting-org ref="XM-DAC-3-1" type="10" xml:lang="EN">
   <narrative xml:lang="EN">Ministry of Foreign Affairs, Denmark</narrative>
  </reporting-org>
  <title xml:lang="EN">
   <narrative xml:lang="EN">Contribution IPM 2017-2020</narrative>
  </title>
  <description type="2" xml:lang="EN">
   <narrative xml:lang="EN">Contribution IPM 2017-2020</narrative>
  </description>
  <participating-org crs-channel-code="30006" role="2" type="30" xml:lang="EN">
   <narrative xml:lang="EN">International Partnership for Microbicides</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-3-1" role="1" type="10" xml:lang="EN">
   <narrative xml:lang="EN">Ministry of Foreign Affairs, Denmark</narrative>
  </participating-org>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A1">
   <owner-org>
    <narrative xml:lang="EN">2017-48190</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A2">
   <owner-org>
    <narrative xml:lang="EN">2017001305</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="B1">
   <owner-org>
    <narrative xml:lang="EN">DK-1</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A3">
   <owner-org>
    <narrative xml:lang="EN">DK-1-270615-32457</narrative>
   </owner-org>
  </other-identifier>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-12-20" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Migration, Stabilization and Fragility</narrative>
   </organisation>
   <person-name>
    <narrative xml:lang="EN">NA</narrative>
   </person-name>
   <email>mns@um.dk</email>
   <mailing-address>
    <narrative xml:lang="EN">Asiatisk Plads 2, 1448 K&#xF8;benhavn K, Denmark</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1"></recipient-region>
  <sector code="130" percentage="100" vocabulary="2" xml:lang="EN">
   <narrative xml:lang="EN">Population Policies/Programmes &amp; Reproductive Health</narrative>
  </sector>
  <sector code="13040" percentage="100" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <country-budget-items vocabulary="4">
   <budget-item code="841" percentage="100" vocabulary="4">
    <description>
     <narrative xml:lang="EN">FL &#xA7;06.36.03.11 SRSR activities with international civil society organisations</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <policy-marker code="5" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <policy-marker code="12" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <budget type="1">
   <period-start iso-date="2017-10-01"></period-start>
   <period-end iso-date="2017-12-31"></period-end>
   <value currency="DKK" value-date="2017-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2018-10-01"></period-start>
   <period-end iso-date="2018-12-31"></period-end>
   <value currency="DKK" value-date="2018-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2019-10-01"></period-start>
   <period-end iso-date="2019-12-31"></period-end>
   <value currency="DKK" value-date="2019-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2020-10-01"></period-start>
   <period-end iso-date="2020-12-31"></period-end>
   <value currency="DKK" value-date="2020-10-01">5000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-12-20"></transaction-date>
   <value currency="DKK" value-date="2017-12-20">20000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-20"></transaction-date>
   <value currency="DKK" value-date="2017-12-20">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-11-15"></transaction-date>
   <value currency="DKK" value-date="2018-11-15">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-11"></transaction-date>
   <value currency="DKK" value-date="2019-12-11">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-14"></transaction-date>
   <value currency="DKK" value-date="2020-12-14">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <related-activity ref="XM-DAC-3-1-270615" type="1"></related-activity>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Clinical trial of vaginal ring</narrative>
   </title>
   <reference code="265954" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="0" measure="1">
    <title>
     <narrative xml:lang="EN">MPT microbicide contraceptive vaginal ring advanced to clinical trials</narrative>
    </title>
    <period>
     <period-start iso-date="2017-01-01"></period-start>
     <period-end iso-date="2017-12-31"></period-end>
     <target value="100"></target>
     <actual value="100"></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Continued clinical trial of vaginal ring</narrative>
   </title>
   <reference code="272104" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">1. Continuation of the Monthly Dapivirine Ring EMA Article 58 Review Process.

2. Preparations for South African Health Products Regulatory Authority (SAHPRA) and US Food and Drug Administration (FDA) filings.

3. Completion of DREAM and HOPE &#x2013; The Dapivirine Ring OLE (Phase IIIB) Trials.

4. Implementation of Access Activities.

5. Continuation of the Clinical Development of Next-generation Dapivirine Rings.</narrative>
    </title>
    <period>
     <period-start iso-date="2018-01-01"></period-start>
     <period-end iso-date="2018-12-31"></period-end>
     <target value="100"></target>
     <actual value="100"></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Continued trial of vaginal ring</narrative>
   </title>
   <reference code="272105" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">The monthly dapivirine vaginal ring, designed to reduce the risk of HIV-1 infection via vaginal intercourse in HIV-negative women in combination with safer sex practices, was submitted under Article 58 in June 2017 to the European Medicines Agency (EMA) and remained under review in 2019.

1. Continuation of the Monthly Dapivirine Ring EMA Article 58 Review Process (seeking a scientific opinion).

2. Announcement of Results from DREAM and HOPE &#x2013; The Dapivirine Ring OLE (Phase IIIB) Trials.

3. Implementation of Access Projects for the Monthly Dapivirine ring.

4. Initiation of Go-to-Market Consultation.

5. Continuation of the Development of Dapivirine Ring Line-Extension Products</narrative>
    </title>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="100"></target>
     <actual value="100"></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Regulatory approval of vaginal ring</narrative>
   </title>
   <reference code="272106" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">1. EMA Issued a Positive Opinion for the monthly DVR.

2. World Health Organization (WHO) Prequalified the DVR.

3. DVR dossier submitted to the South African Health Products Regulatory Authority (SAHPRA) and the US Food and Drug Administration (FDA).

4. Access and Market Research to inform DVR rollout continued.

5. Continuation of the Development of Dapivirine Ring follow-on Products.</narrative>
    </title>
    <period>
     <period-start iso-date="2020-01-01"></period-start>
     <period-end iso-date="2020-12-31"></period-end>
     <target value="100"></target>
     <actual value="100"></actual>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
